<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785770</url>
  </required_header>
  <id_info>
    <org_study_id>B0401018</org_study_id>
    <nct_id>NCT02785770</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of Pf-04447943 On Qtc Interval In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study designed to ascertain the effect of PF-04447943 on QT interval in healthy
      adult subjects. This is conducted as part of standard drug development.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time matched mean differences in QTc interval using Fridericia's correction method (QTcF), or other correction method if warranted, between PF 04447943 and placebo at each post dose time point</measure>
    <time_frame>-1, -0.5, 0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time matched mean differences in QTcF of moxifloxacin and placebo at historical moxifloxacin median Tmax of 3 hours</measure>
    <time_frame>-1, -0.5, 0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time matched mean differences in heart rate between PF-04447943 and placebo</measure>
    <time_frame>-1, -0.5, 0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>0-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Signs Findings (Including Bood Pressure and Pulse Rate) of Potential Clinical Importance</measure>
    <time_frame>0-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance</measure>
    <time_frame>0-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-04447943</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-04447943</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-04447943</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time matched mean differences in PR intervals between PF-04447943 and placebo</measure>
    <time_frame>-1, -0.5, 0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time matched mean differences in QRS intervals between PF-04447943 and placebo</measure>
    <time_frame>-1, -0.5, 0, 0.5, 1, 2, 3, 4, 8, 12, 24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-04447943 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg of PF-04447943</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04447943 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of PF-04447943</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for PF-04447943</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg of moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04447943</intervention_name>
    <description>Single oral dose of PF-04447943 administered as an extemporaneously prepared solution</description>
    <arm_group_label>PF-04447943 low dose</arm_group_label>
    <arm_group_label>PF-04447943 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Single oral dose of moxifloxacin administered as tablet</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects of non childbearing potential and/or healthy male subjects,
             between the ages of 18 and 55 years.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  History of cerebrovascular accident, transient ischemic attack (TIA), or traumatic
             brain injury.

          -  History of seizures or history or physical examination findings (eg localizing signs
             on neurologic examination) suggestive of structural central nervous system (CNS)
             abnormalities which may place patient at increased risk of seizures.

          -  History of orthostatic blood pressure changes or clinically significant orthostatic
             symptoms.

          -  Self reported history or risk factors for QT prolongation or torsades de pointes (eg,
             organic heart disease, congestive heart failure, hypokalemia, hypomagnesaemia,
             congenital long QT syndrome, myocardial ischemia or infarction), congenital deafness,
             family history of sudden death, and family history of long QT syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0401018&amp;StudyName=A+Phase+1%2C+Single-dose%2C+Randomized%2C+4-treatment%2C+4-period+Crossover%2C+Placebo-+And+Positive-controlled%2C+Double-blind+%28open-label+For+Positive+Control%29%2C+Sponsor-open+Study+To+Determine+The+Effect+Of+Pf-04447943+On+Qtc+Interval+In+Healthy+Adult+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 5, 2017</submitted>
    <returned>May 25, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

